Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12305-12315

  Zhao, Jun gang ^a   Ren, Kai ming ^a   Tang, Jun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

5 Fu; Cisplatin; Glucose metabolism; Human non small cell lung cancer cells

Indexed keywords

CISPLATIN; FLUOROURACIL; GLUCOSE;

ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GLYCOLYSIS; HUMAN; LUNG NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; GLUCOSE; GLYCOLYSIS; HUMANS; LUNG NEOPLASMS; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925283203     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2543-3     Document Type: Article

References (26)

1. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, uft, s-1): a review. Oncologist. 2002;7:288–323.
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.
3. DeBraud F, Munzone E, Nole F, De Pas T, Biffi R, Brienza S, et al. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol. 1998;21:279–83.
4. Zhang N, Yin Y, Xu SJ, Chen WS. 5-fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551–69.
5. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275–92.
6. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of bcl-2 and bcl-x(l) in addition to bax and p53 status. Int J Cancer. 2002;98:498–504.
7. Zhu H, Guo W, Zhang L, Davis JJ, Teraishi F, Wu S, et al. Bcl-xl small interfering rna suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther. 2005;4:451–6.
8. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncol Basel. 2002;62:354–62.
9. Grem JL. Screening for dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 2005;11:5067–8.
10. Arnold CN, Goel A, Boland CR. Role of hmlh1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003;106:66–73.
11. Vander HM, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
12. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532.
13. Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL, et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 2010;101:1447–53.
14. Ayyanathan K, Kesaraju S, Dawson-Scully K, Weissbach H. Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PLoS One. 2012;7:e39949.
15. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.
16. Egawa-Takata T, Endo H, Fujita M, Ueda Y, Miyatake T, Okuyama H, et al. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. Cancer Sci. 2010;101:2171–8.
17. Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A, Gottesman MM. Sirt1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res. 2008;6:1499–506.
18. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol. 2007;59:495–505.
19. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, et al. 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004;64:31–4.
20. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 2011;71:4585–97.
21. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71:523–30.
22. Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, Jalali R, et al. Clinical studies for improving radiotherapy with 2-deoxy-d-glucose: present status and future prospects. J Cancer Res Ther. 2009;5 Suppl 1:S21–6.
23. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99:989–94.
24. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat. 2010;120:253–60.
25. Tong J, Xie G, He J, Li J, Pan F, Liang H. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol. 2011;2011:740564.
26. Hur H, Xuan Y, Kim YB, Lee G, Shim W, Yun J, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 2013;42:44–54.